is an attractive target for the development of therapeutics against SARS due to its fundamental role in viral 1 McMaster High Throughput Screening Laboratory Department of Biochemistry replication. Homology modeling with other 3CL pro 's [12, 15], X-ray crystallography [13], and a recent mutagene-McMaster University Hamilton, Ontario L8N 3Z5 sis study [16] have identified 3CL pro as a cysteine protease with a Cys-His catalytic dyad in the active site. Canada 2 Departments of Microbiology and Biochemistry Structure-based sequence alignments of pp1a and pp1ab of SARS-CoV with the equivalent polyproteins University of British Columbia Vancouver, British Columbia V6T 1Z3 from human coronavirus 229E (HCoV), porcine transmissible gastroenteritis virus (TGEV), bovine coronavirus Canada (BCoV), and avian infectious bronchitis virus (IBV) have identified the consensus sequence for proteolysis as (S, T, V, P, A)-(L, I, V, F, M)-Q/(A, S, G, N, C) [12]. In vitro Summary studies have confirmed the ability of 3CL pro to process sites of this type, and that the proteinase has the highest The causative agent of severe acute respiratory syndrome (SARS) has been identified as a novel coronavi-specificity for the cleavage sites flanking 3CL pro in the pp1a/pp1ab polyprotein [11, 17]. rus, SARS-CoV. The main proteinase of SARS-CoV, 3CL pro , is an attractive target for therapeutics against A structural model of 3CL pro based on sequence homology with TGEV [12] as well as the solved crystal SARS owing to its fundamental role in viral replication. We sought to identify novel inhibitors of 3CL pro to ad-structure [13] have both been used in a number of studies to dock substrate mimics [12, 13, 18] and for virtual vance the development of appropriate therapies in the treatment of SARS. 3CL pro was cloned, expressed, and screening of collections of synthetic compounds, natural products, and approved antiviral therapies to evalu-purified from the Tor2 isolate. A quenched fluorescence resonance energy transfer assay was devel-ate their ability to inhibit 3CL pro [15, 19-22]. Compounds identified as potential inhibitors of 3CL pro from these oped for 3CL pro to screen the proteinase against 50,000 drug-like small molecules on a fully automated sys-studies include the HIV-1 protease inhibitor L-700,417 [15], the reverse transcriptase inhibitors calanolide A tem. The primary screen identified 572 hits; through a series of virtual and experimental filters, this number and nevirapine [20], glycovir, an ␣-glucosidase inhibitor [20], sabadinine, a natural product [21], and the general was reduced to five novel small molecules that show potent inhibitory activity (IC 50 ϭ 0.5-7 M) toward antiviral ribavirin [20] . Ribavirin has been shown to exhibit anti-SARS-CoV activity in vitro, but at concentra-SARS-CoV 3CL pro . tions that are cytotoxic [23]. At the onset of the initial SARS outbreak, this compound was used as a first-line Introduction defense both as a monotherapy [24] and in combination with corticosteroids [25] or Kaletra (an approved HIV The first wave of Severe Acute Respiratory Syndrome (SARS) was successfully contained by the summer of protease inhibitor) [24]; however, it is now generally believed that ribavirin is not an effective treatment for SARS 2003 [1], but not until close to 8500 people worldwide were infected, and over 900 had died [2]. Upon the emer-([26, 27] and references therein). At the time of writing, it is not known whether the other compounds identified gence of this syndrome, international response was quick to identify and characterize its causative agent as through virtual means have yet been tested with 3CL pro or SARS-CoV to evaluate their actual inhibitory capabil-a novel coronavirus, SARS-CoV [3-7]. The reemergence ities. of SARS in the Guangdong province of China in Decem-Several in vitro screens have also been recently reber 2003 [8] and the spring of 2004 [9], while not necesported that have assessed the ability of existing proteinsarily indicative of another global outbreak, illustrates ase inhibitors to inhibit replication of SARS-CoV and, the need to continue efforts to study this virus and dein some cases, 3CL pro specifically. The HIV-1 protease velop appropriate therapeutics for its treatment. inhibitors indinavir, saquinavir, ritonavir, lopinavir, TYA5, SARS-CoV is an enveloped, positive-stranded RNA TYB5, and KNI-272 were shown to be ineffective at inhibvirus whose genome is predominated by two open readiting replication of SARS-CoV in vitro [23, 28]. Another ing frames that are connected by a ribosomal frameshift HIV-1 protease inhibitor, nelfinavir, was shown to inhibit site and that encode the two replicase proteins, pp1a SARS-CoV replication with an EC 50 of 48 nM [28], yet it and pp1ab [10, 11]. These polyproteins are cleaved by has also been reported that complete inhibition of viral the main proteinase 3CL pro [11] (also called M pro [12, 13]) replication was not seen with compound concentrations up to 10 M [23]. Another in vitro screen that similarly *Correspondence: ebrown@mcmaster.ca (E.D.B.); leltis@interchange. tested a library of 500 protease inhibitors resulted in ubc.ca (L.D.E.) 3 These authors contributed equally to this work.
had been developed as a transition-state analog inhibitor for HIV-1 protease and had a K i of 0.6 M with 3CL pro [29] .
Although a number of existing drugs that could potentially act as inhibitors of 3CL pro were identified through virtual screening, other than ribavirin, it is not known how active these compounds actually are toward the protease. Additionally, in vitro screening campaigns illustrate that out of over 500 existing protease inhibitors, only two were identified as active toward 3CL pro . These findings illustrate the need to look toward the development of innovative inhibitors for this protease. One such study has recently identified unique keto-glutamine analogs as inhibitors of 3CL pro with IC 50 's in the low micromolar range (J.C. Vederas, submitted). In an effort to advance this initiative, we sought to identify novel small molecules that specifically target 3CL pro . In this paper, we describe the cloning, expression, and purification of 3CL pro from the SARS-CoV Tor2 isolate, and subsequent In order to screen SARS-CoV 3CL pro against a library of are spatially separated; subsequent fluorescence from the Abz functionality is not quenched and can be detected. 50 ,000 compounds, it was necessary to use an activity assay for the proteinase that could be adapted to an automated system. Ideally, such an assay would (1) work of kinetic data using the Abz-Tyr(NO 2 ) substrate, the over a time scale of several minutes at most to facilitate primary data were corrected for inner filter effect [31] . the rapid evaluation of thousands of potential inhibitors;
This adjustment was essential as it was observed that (2) be homogeneous for ease of automation; and (3) at even relatively low concentrations of substrate (2 M), be sensitive to minimize background signal from the the fluorescence of the cleaved product was signifipresence of the compounds tested. Quenched fluorescantly quenched by the nitrotyrosine moiety of the intact cence resonance energy transfer (FRET) assays have substrate. become a common tool to monitor proteinase activity The K m for the Abz-Tyr(NO 2 ) substrate with 3CL pro was [30] and fulfill the necessary criteria for use in an efficient 820 Ϯ 130 M (Figure 2A ). This value is comparable to and robust high-throughput screening (HTS) campaign. those seen recently for nonlabeled 11-mer peptides that The basis for such an assay is the modification of a also mimic the cleavage sites of the natural substrates peptide substrate to include a fluorescent label and of 3CL pro (0.286-1.94 mM) [17], implying that the labels quencher on opposing sides of the proteinase cleavage incorporated for FRET were not detrimental to the assosite (Figure 1 ). Using this substrate, the activity of a ciation between enzyme and substrate. The calculated proteinase can be measured directly without the need values of the apparent k cat and k cat /K m for the labeled for additional steps to purify and/or characterize the substrate were 1.01 Ϯ 0.09 min Ϫ1 and 1.2 Ϯ 0.2 mM Ϫ1 products. This type of assay is also beneficial as it permin Ϫ1 respectively, and were also similar to those remits enzymatic reactions to be monitored in real time to obtain accurate reaction rates. This aspect of the quenched-FRET assay is particularly attractive since, in evaluating the activity of a proteinase in terms of a rate, the potential for false negatives to occur in the screen due to the presence of inherent fluorescence from the compounds being tested is reduced.
Two fluorogenic peptide substrates were synthesized to develop a continuous assay of 3CL pro proteolytic activity based on FRET. The peptides were designed principally on the sequences flanking 3CL pro in the polyprotein and solubility considerations. A peptide incorporating the anthranilate-nitrotyrosine donor-acceptor pair (Abz- and was the preferred substrate for HTS. In the analysis also illustrates the quality of the screen in terms of the to be monomeric, whereas it is the dimeric form of the reproducibility between the duplicate sets of data. This enzyme that is believed to be catalytically competent.
figure also indicates that 3CL pro appears to have been For the purposes of screening, it is desirable to use the inhibited to some degree by a large number of comlowest concentration of substrate that yields a reliable, pounds. The cutoff to determine the hit threshold was reproducible signal. It was found that assays using 100 set to 50% residual enzyme activity in order to focus M of the fluorogenic peptide gave a strong signal that on the most potent inhibitors. was linear with varying 3CL pro concentration ( Figure 2B) .
Five hundred and seventy-two hits (1.1% hit rate) were This enabled us to screen at substrate concentrations identified from the primary screen of 3CL pro . For the well below K m , which is advantageous for identifying preliminary analyses of these hits, we opted to restrict inhibitors that compete with substrate for the enzyme the number of compounds entering secondary screenactive site [33] and are therefore more likely to be speing by a series of virtual and experimental filters. The cific toward 3CL pro . hits were first classified by recursive partitioning into The compound library used to screen 3CL pro contained 126 groups based on similarities between molecular 50,000 small molecules with an average molecular mass structure and activity in the primary screen [37, 38] . of 325 g/mol. This particular collection was screened Within each of these groups, the compound that strongly because of its high quality, diversity, drug-likeness [34] , inhibited 3CL pro was chosen as a representative candiresupply availability, and past success with other targets date for further study in secondary analyses. The dose- [35] . The campaign was run in duplicate in 384-well response curves of the 126 representative compounds microplate format on a fully automated system. were determined using standard assay conditions (100 The statistical parameter ZЈ, which is described as a M substrate, 1 M 3CL pro ) and 90 nM-100 M of tested measure of the quality of an HTS campaign [36] , is decompound. The dose-response relationship of 72 comfined as pounds resulted in the typical sigmoidal semilogarithmic curve associated with desirable inhibitors; the 54 com-
(1) pounds that did not result in this typical curve were filtered out. To eliminate nonspecific inhibitors, the effect of the where cϩ , cϪ , cϩ , and cϪ are the standard deviations () and averages () of the high ( cϩ ) and low ( cϪ ) controls.
remaining 72 compounds on 3CL pro activity in the presence of bovine serum albumin (BSA) was determined. This value reflects both the error associated with the controls of a screen, as well as the size of the "hit win-If the degree of inhibition of 3CL pro by a compound is decreased in the presence of BSA, inhibition is not likely dow" (Figure 3) . A ZЈ of 0.5 or greater is indicative of a quality screen with a well-defined hit window [36] . The to be targeted exclusively toward 3CL pro . These socalled "promiscuous" inhibitors likely form aggregates ZЈ for the primary screen of SARS-CoV 3CL pro was 0.60 for each of the two replicates indicating that the assay in solution that nonspecifically absorb or adsorb the target enzyme [39] . Only three compounds showed any used to detect activity of 3CL pro was robust and amenable to HTS. The replicate plot of residual enzyme activity marked reduction in enzyme inhibition in the presence The sum of the number of compounds in each group is greater than 69 as several compounds contained more than one of the listed functionalities.
of BSA, with the greatest effect being a decrease of though this renders such compounds as unlikely drug candidates, they may be useful in studying the active only 20%; these compounds were removed from the prospective inhibitor pool. site architecture of 3CL pro . Of the remaining 69 candidate inhibitors, the inhibitory action of 5 of these was not The remaining 69 potential candidates were predominated by compounds with at least one potentially reac-significantly affected by the inclusion of 1 mM DTT; these were selected for further characterization. tive center (Table 1) 
. The thiol side chain of the active site cysteine of 3CL pro is necessarily a good nucleophile
The dose-response curves for these five compounds with 3CL pro yielded IC 50 values of 0.5-7 M ( Figure 5) . and therefore has the capacity to combine with a variety of electrophilic functionalities to form covalent adducts. Table 1 , It was difficult in some cases to obtain a full doseresponse curve for every inhibitor with each of the pro-5-12, may also have enough electrophilic character to promote the nucleophilic attack of the active site thiol teinases due to interfering compound fluorescence and/ or compound insolubility under each of the assay condi-of 3CL pro . Due to the potential inherent reactivity of the 69 candidate inhibitors, we sought to identify and eliminate tions. In such cases, if the lack of data at higher compound concentrations precluded interpolation of a reli-those compounds whose high reactivity rendered them nonspecific toward the active site of 3CL pro by including able IC 50 value, the IC 50 is reported as a lower limit (Table  2) . Alternatively, those compounds for which enzyme 1,4-dithio-D,L-threitol (DTT) in the inhibition reaction. A reduction in the inhibition of 3CL pro by any candidate inhibition was not seen at the highest concentration tested, are indicated accordingly. It is important to note compound in the presence of DTT suggests that such a compound would probably react nonspecifically with that in the absence of full mechanistic analyses, the IC 50 values are intended to reveal profound differences in any biologically available thiol functionality [40, 41] . Al-Considering the mechanistic and structural relationships between 3CL pro and HAV 3C pro , and to a lesser extent NS3 pro , we were interested to learn that some of the compounds showed highest activity against these related enzymes. In addition to inhibiting 3CL pro with an IC 50 of 7 M, compound MAC-30731 was observed to have relatively potent activity against HAV 3C pro (IC 50 ϭ 54 M) and NS3 pro (IC 50 ϭ 71 M), with only weak impact on chymotrypsin (IC 50 Ͼ 800 M).
To evaluate the selectivity of each compound, we investigated their ability to inhibit four other proteinases with This reaction is the basis for several classes of existing peptidic inhibitors of cysteine proteases which include varying structural and mechanistic relatedness to SARS-
MAC-8120 and MAC-13985 also demonstrated interesting selectivity profiles with good activity against SARS-CoV 3CL pro (IC 50 values were 4.3 and 7 M, respectively) and no detectable inhibition of any of the other proteinases tested. These particular compounds, however, proved to be difficult in the assays of HAV 3C pro and NS3 pro due to background fluorescence, and could not be tested at concentrations greater than 5 M. Nevertheless, no detectable inhibition was seen at that concentration, indicating that an IC 50 for these molecules would necessarily be much higher.
The protease selectivity data, therefore, point to two molecules with apparent selectivity for 3CL pro , MAC-8120 and MAC-13985. These may well be the most promising leads for further mechanistic characterization and optimization efforts toward a protease-based antiviral for SARS-CoV. One molecule, MAC-30371, has an interesting selectivity for the picornaviral-like proteinases and could prove to be a viable lead for this family of proteolytic enzymes. 
yeast (IC 50 ϭ 56 M to 4 mM) [47]. This study examined the inhibition of the isomerase by a series of substituted potency to provide insight into the selectivity of the benzothiazoles, and indicated that MAC-8120 interinhibitors, and to aid in their prioritization as leads for
acted with cysteine residues on the enzyme that were continuing studies. previously shown to be central in dimerization. This in-Compound MAC-22272 showed the least selectivity teraction, although as yet uncharacterized, was reported with respect to 3CL pro (IC 50 ϭ 2.6 M), as it was the only to perturb the contact interface of the subunits of the inhibitor capable of inactivating all of the proteinases homodimer to inactivate the enzyme. It is therefore quite studied, although the response with NS3 pro (IC 50 Ͼ 500 possible that MAC-8120 associates with the active site M) was significantly lower than with the other enzymes. cysteine of 3CL pro in a similar manner to disrupt its cata-MAC-5576 showed some selectivity toward those prolytic activity. The exact mechanism of inhibition of 3CL pro teinases with a chymotrypsin-like fold, as it was seen by MAC-8120 and the remaining secondary hits requires to inhibit 3CL pro (IC 50 ϭ 0.5 M), HAV 3C pro (IC 50 ϭ 0.5 further study and characterization in order to evaluate M), and chymotrypsin (IC 50 ϭ 13 M), although no effect their potential to act as leads for the development of was seen with NS3 pro , which also shares this structural novel therapeutics against SARS-CoV, and potentially, motif. Papain, which lacks this fold, was unaffected by other picornaviral-like proteinases. Additionally, the
MAC-5576. An important difference between 3CL pro and core structure of these compounds can be chemically 3C pro is that the coronaviral enzyme is only functionally modified to improve key physical properties such as active as a dimer whereas 3C pro is active as a monomer potency and solubility. in vitro. The interaction between the 3CL pro subunits is
It is clearly evident that the 3CL pro screening campaign sufficiently weak that disrupting the dimerization interhas generated a wealth of data that can be mined for a face has been proposed as a promising target for novel number of studies. While it was our intention to identify antiviral agents [32] . In view of the relatedness between novel small molecules that would lead to the develop-3CL pro and HAV 3C pro , it is therefore likely that of the five ment of therapeutics effective against SARS-CoV, the secondary hits, those that are also active toward HAV results generated by the screening campaign can be 3C pro do not interact with 3CL pro at its dimer interface, applied to other types of studies of 3CL pro and related proteinases including the picornaviral 3C pro . To this end, but at a site that is common to both proteinases. Table 2 
. Summary of IC 50 Values of the Five Secondary Hits with SARS-CoV 3CL pro and Four Other Proteases

